<?xml version="1.0" encoding="UTF-8"?>
<p>The seventh edition of the Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment published by China National Health Commission on 4 March 2020 included tocilizumab as an option for patients with severe COVID-19, extensive lung lesions, and elevated IL-6 levels [
 <xref rid="B90-pharmaceuticals-13-00096" ref-type="bibr">90</xref>]. This followed reports of positive outcomes from the use of tocilizumab to control dangerous lung inflammation in 21 patients with severe COVID-19 in China [
 <xref rid="B91-pharmaceuticals-13-00096" ref-type="bibr">91</xref>].
</p>
